Psoriatic Arthritis

Which came first: the psoriatic arthritis or the cardiovascular risk factors?

Are you up-to-date on the latest recommendations for PsA from EULAR and GRAPPA? Take our 6-question quiz to find out.

What's new: reliable outcome measures, overlap in treatment targets, and immune checkpoint inhibitors.

Findings from the first real-world study of gaps in care for hypertension and dyslipidemia in patients with psoriasis and psoriatic arthritis.

Various biologics that focus on the IL-17 pathway are currently being studied.

British investigators take a long-range view of tumor necrosis factor inhibitors in patients with psoriatic arthritis.

An expanded role for MRI and 2 recently approved treatment options.

New data highlight the role of the C5a-C5aR axis in the onset of inflammation.

Moderate to high disease activity may persist.

The Biologics License Application is for another biosimilar to AbbVie's best-selling Humira drug.

The trial is the first head-to-head clinical comparison in ankylosing spondylitis investigating the superiority of secukinumab for slowing spinal bone damage versus proposed biosimilar adalimumab.

This is the only fully human anti-TNF-α infused therapy approved for psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.

Previously approved for moderate-to-severe rheumatoid arthritis, golimumab received 2 new indications.

The drug is the first and only fully-human antagonist showing sustained skin clearance rates at 5 years.

Patients demonstrated improved disease response in 2 clinical trials.

When inflammatory arthritis develops in the context of Lyme disease, clinicians have three options, experts say.

Patients with inflammatory arthritis are being treated for cardiovascular risk factors at rates similar to that of the general population, even though their risk is higher, study shows.

Clinical enthesitis is a common condition for some psoriatic arthritis patients who are disproportionately affected by inflammation, particularly of the Achilles tendon, plantar fascia and lateral epicondyle.

Redefining disease remission or inactivity examined in this assessment by Laura Coates of the University of Leeds.

Experts now believe that psoriatic arthritis should be considered a risk factor for cardiovascular diseases, including stroke.

When a patient presents with a history of Lyme disease and joint pain, refractory Lyme arthritis seems reasonable, but then, this study warns of systemic arthritis after a Lyme disease infection.

A retrospective analysis of patient records has found a significant link between psoriatic arthritis and malignant cancer – particularly breast cancer.